Microsoft and Adaptive announce opening of ImmuneCODE database to accelerate research and development of COVID-19 vaccine

In response to the global pandemic of the new coronavirus, multi-national medical teams are eagerly developing the COVID-19 vaccine. In March, Microsoft and Adaptive Biotechnology announced an expanded partnership. Now, they have announced the opening of the ImmuneCODE database to accelerate the development of the COVID-19 vaccine. The database compiles data from blood samples from thousands of COVID-19 patients around the world.

Microsoft and Adaptive announce opening of ImmuneCODE database to accelerate research and development of COVID-19 vaccine

Screenshot of the video (from: Microsoft)

Through the ImmuneCODE database, researchers can access detailed data and resources on THE COVID-19 immune response in real time to drive better diagnostic methods, the development of COVID-19 vaccines and drugs, and answer important questions about the new coronavirus.

“Adaptive biotechnology raises a very bold, manageable, machine learning question for T-cell sequencing, but gives us the opportunity to classify and share it,” said Peter Lee, Microsoft’s vice president of research and incubation.

Decoding the COVID-19 Immune Response (via)

By opening the ImmuneCODE database free of charge worldwide, we can deepen our collective understanding of the human immune response and help researchers accelerate the development of related drugs and vaccines in response to this global health crisis.